1563182-99-9

Upstream product

• 1563182-50-2 (S)-2-(3,4-dichlorophenyl)-2-methylpent-4-enoic acid 
• 619254-64-7 2-(3,4-dichlorophenyl)-2-methylpent-4-enoic acid 
• 1563182-98-8 (S)-3-(3,4-dichlorophenyl)-5-hydroxy-3-methyldihydrofuran-2(3H)-one 
• 67677-81-0 1-methylspiro<3H-indole-3,4'-piperidin>-2(1H)-one 
• 619254-63-6 methyl 2-(3,4-dichlorophenyl)-2-methylpent-4-enoate 
• 1563182-51-3 C₁₂H₁₂Cl₂O₂*C₈H₁₁N 
• 173457-29-9 2-(3,4-dichloro-phenyl)-pent-4-enoic acid methyl ester 
• 5807-30-7 3,4-dichlorophenyl acetic acid 

Downstream Products

• 1563183-01-6 2-((S)-2-((S)-2-(3,4-dichlorophenyl)-2-methyl-4-(1-methyl-2-oxospiro[indoline-3,4'-piperidine]-1'-yl)butanamido)-3-phenylpropanamido) ethyl carbamic acid benzyl ester 

Relevant academic research and scientific papers

Design, synthesis, and optimization of balanced dual NK1/NK 3 receptor antagonists

In connection with a program directed at potent and balanced dual NK 1/NK3 receptor ligands, a focused exploration of an original class of peptidomimetic derivatives was performed. The rational design and molecular hybridization of a novel phenylalanine core series was achieved to maximize the in vitro affinity and antagonism at both human NK1 and NK3 receptors. This study led to the identification of a new potent dual NK1/NK3 antagonist with pKi values of 8.6 and 8.1, respectively.